

SN 09/943,531

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: RISINGER et al  
Serial No.: 09/943,531  
Filed: August 30, 2001  
Title: Detection of CYP2C19 Polymorphisms

Examiner: SAKELARIS, SALLY A  
Group Art Unit: 1634  
Docket: SGL-2020-UT

**COMMUNICATION**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

Applicants herewith submit the documents as listed in PTO/SB/08A Form in compliance with 37 CFR § 1.97(b), after the mailing date of the first office action on the merits, but prior to the final office action. Applicants submitted payment of \$180.00 with the previously filed response as indicated in the courtesy copy of the documents provided herewith.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date 8 AUGUST 2005  
BioTechnology Law Group  
658 Marsolan Ave.  
Solana Beach, CA 92075  
Telephone: (858) 623-9470  
Fax: (858) 623-9476  
Email: bruce@biotechnologylawgroup.com

By

Bruce Grant  
Reg. No. 47,608

**CERTIFICATE OF TRANSMISSION/MAILING**


I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

8 AUGUST 2005  
Date

Signature

Bruce Grant

Printed Name



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number 09/943,531

Filing Date 08/30/2001

First Named Inventor RISINGER

Art Unit 1634

Examiner Name SAKELARIS, SALLY A

Attorney Docket Number SGL-2020-UT

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<b>Remarks</b>	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Transmittal (1 page)	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Courtesy Copy of SB08 - 3 pages	
	Cover letter - 1 pages	
	Courtesy copy of Supplemental Information Disclosure Statement (2 pages)	
	return Post card - 1 page	
	enclosed 55 documents	

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Biotechnology Law Group		
Signature			
Printed name	BRUCE D. GRANT		
Date	8 AUGUST 2005	Reg. No.	47,608

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	BRUCE D. GRANT	Date	8 AUGUST 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Application No. 09/943,531

COPY

PATENT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: RISINGER et al

Examiner: SAKELARIS, SALLY A

Serial No.: 09/943,531

Group Art Unit: 1634

Filed: August 30, 2001

Docket: SGL-2020-UT

Title: DETECTION OF CYP2C19 POLYMORPHISMS

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication. Applicants also bring to the Examiner's attention the existence of two co-pending related applications: (1) application no. 09/942,310 (Attorney Docket: SGL-2019-UT), filed August 29, 2001 and published March 6, 2003 as US20030044797 A1 (Examiner Jeanine Anne Goldberg), and (2) application no. 09/943,115 (Attorney Docket: SGL-2021-UT), filed August 30, 2001 (Examiner Diana B. Johannsen).

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), after the mailing date of the first office action on the merits, but prior to the final office action.

Accordingly, Applicants respectfully submit payment of \$180.00.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date 15 July 2005

BioTechnology Law Group

658 Marsolan Ave.

Solana Beach, CA 92075

Telephone: (858) 623-9470

Fax: (858) 623-9476

Email: [bruce@biotechnologylawgroup.com](mailto:bruce@biotechnologylawgroup.com)

By

  
Bruce Grant


Reg. No. 47,608

CERTIFICATE OF EXPRESS MAIL TRANSMISSION


The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage via Express Mail Post Office to Addressee (Express Mail Label No. **ER 157511790 US**), in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

15 July 2005

Date

  
Bruce Grant

# COPY



PTO/SB/06A(06-03)  
Approved for use through 07/31/2006 OMB 0651-0031  
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 1 of 3

Attorney Docket No: SGL-2020-UT

## US PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,656,127	04/07/1987	MUNDY	
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	
	A3.	4,683,202	07/28/1987	MULLIS	
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	06/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	06/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	


EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/06A(08-03)  
 Approved for use through 07/31/2009, OMB 0651-0031  
 US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Complete if Known**

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 2 of 3

Attorney Docket No: SGL-2020-UT

**US PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGENS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTROEDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

**FOREIGN PATENT DOCUMENTS**

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

AUG 10 2005

Sheet 3 of 3

**Complete if Known**

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Attorney Docket No: SGL-2020-UT

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	A39.	WO0120039	03/22/2001	ROTHBERG and BADER		
	A40.	WO0127326	04/19/2001	EGHOLM and CHEN		
	A41.	WO0127327	04/19/2001	BRENNAN and CHATELAIN		
	A42.	WO0127329	04/19/2001	MACLEOD and ALDAZ		
	A43.					
	A44.					

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A45.	ANDERSON et al., Pharmacogenetics., 2(1):25-31 (1992)	
	A46.	BALIAN et al., Clin. Pharmacol. Ther., 57(6):662-669 (1995)	
	A47.	BERTILSSON, Clin. Pharmacokinet., 29(3):192-209 (1995)	
	A48.	CHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	
	A49.	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)	
	A50.	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)	
	A51.	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)	
	A52.	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)	
	A53.	IBEANU et al., J. Pharmacol. Exp. Ther., 290(2):635-640 (1999)	
	A54.	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)	
	A55.	MACAULAY et al., Science, 308:1034-1036 (2005)	
	A56.	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)	
	A57.	RICHARDS et al, Am. J. Hum. Genet. 67:1251-1276 (2000)	
	A58.	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)	
	A59.	WILKINSON et al., Pharmac. Ther. 43:53-76 (1989)	
	A60.	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)	
	A61.		
	A62.		

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional) \* Applicant is to place a check mark here if English language Translation is attached